<- Go Home
GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Market Cap
$1.2B
Volume
1.2M
Cash and Equivalents
$133.9M
EBITDA
-$496.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$76.0M
Profit Margin
58.18%
52 Week High
$63.99
52 Week Low
$12.33
Dividend
N/A
Price / Book Value
N/A
Price / Earnings
-0.56
Price / Tangible Book Value
N/A
Enterprise Value
$550.6M
Enterprise Value / EBITDA
-1.16
Operating Income
-$654.0M
Return on Equity
62.22%
Return on Assets
-11.99
Cash and Short Term Investments
$674.6M
Debt
$64.3M
Equity
$2.4B
Revenue
$130.7M
Unlevered FCF
-$236.9M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium